Subscribe to our newsletter to receive the latest product updates and special offers

Upgrade to FINVIZ*Elite to get real-time quotes, intraday charts, and advanced charting tools.

NEW: Earnings

Review historical estimates and see whether a company has beaten or missed expectations.

Last Close
Jun 13 04:00PM ET
0.9500
Dollar change
-0.0300
Percentage change
-3.06
%
Index- P/E- EPS (ttm)-1.67 Insider Own14.04% Shs Outstand16.01M Perf Week-7.77%
Market Cap15.21M Forward P/E- EPS next Y- Insider Trans0.00% Shs Float13.76M Perf Month-26.07%
Income-26.77M PEG- EPS next Q- Inst Own14.67% Short Float10.33% Perf Quarter-42.07%
Sales0.01M P/S1520.95 EPS this Y- Inst Trans22.32% Short Ratio30.49 Perf Half Y41.69%
Book/sh0.30 P/B3.17 EPS next Y- ROA-97.94% Short Interest1.42M Perf Year-86.23%
Cash/sh0.26 P/C3.67 EPS next 5Y- ROE-156.09% 52W Range0.66 - 7.96 Perf YTD-10.42%
Dividend Est.- P/FCF- EPS past 5Y21.41% ROI-558.14% 52W High-88.06% Beta-0.45
Dividend TTM- Quick Ratio4.87 Sales past 5Y86.87% Gross Margin-47233.33% 52W Low43.94% ATR (14)0.10
Dividend Ex-Date- Current Ratio4.87 EPS Y/Y TTM34.48% Oper. Margin-342716.67% RSI (14)34.08 Volatility9.40% 9.88%
Employees1 Debt/Eq0.00 Sales Y/Y TTM-99.79% Profit Margin-446233.33% Recom3.00 Target Price112.50
Option/ShortYes / Yes LT Debt/Eq0.00 EPS Q/Q83.30% Payout- Rel Volume0.20 Prev Close0.98
Sales Surprise- EPS Surprise-14.29% Sales Q/Q- Earnings- Avg Volume46.63K Price0.95
SMA20-12.56% SMA50-24.91% SMA200-39.12% Trades Volume9,508 Change-3.06%
Date Action Analyst Rating Change Price Target Change
Oct-04-22Resumed Wells Fargo Overweight $3
May-15-24 10:55PM
Apr-08-24 12:52PM
Dec-18-23 07:57AM
Nov-14-23 07:56AM
07:30AM
04:05PM Loading…
Aug-14-23 04:05PM
Jun-29-23 07:00AM
May-25-23 05:00PM
May-10-23 07:00AM
May-03-23 08:30AM
Apr-26-23 12:30PM
Mar-30-23 07:00AM
Mar-29-23 05:30PM
Mar-07-23 07:00AM
Feb-28-23 04:01PM
05:47AM Loading…
Feb-17-23 05:47AM
Jan-09-23 08:30AM
Nov-29-22 09:01AM
Nov-28-22 04:01PM
Nov-14-22 07:00AM
Nov-08-22 08:30AM
Nov-07-22 08:00AM
Sep-21-22 08:30AM
Sep-07-22 08:30AM
Sep-06-22 08:00AM
Aug-24-22 03:00PM
Aug-15-22 07:00AM
Aug-08-22 08:50AM
Aug-04-22 05:00PM
Jul-06-22 09:31AM
07:07AM Loading…
Jun-30-22 07:07AM
Jun-27-22 08:00AM
Jun-01-22 08:30AM
May-26-22 05:01PM
May-16-22 07:30AM
May-12-22 11:48AM
May-10-22 08:30AM
May-09-22 08:30AM
May-02-22 04:31PM
08:30AM
Mar-30-22 07:30AM
Mar-22-22 01:58PM
Mar-16-22 08:30AM
Mar-08-22 04:05PM
Alaunos Therapeutics, Inc. is a biopharmaceutical company and clinical-stage oncology-focused cell therapy company, which engages in the development of adoptive TCR engineered T-cell therapies, or TCR-T, designed to treat multiple solid tumor types in large cancer patient populations with unmet clinical needs. Its pipeline includes Library TCR-T cell and mblL-15 TCR-T cell Therapy. The company was founded in 2003 and is headquartered in Houston, TX.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
Boyle Kevin S. Sr.Chief Executive OfficerSep 01 '23Sale0.1468,0149,542798,236Sep 05 05:34 PM